文章：

破坏细胞周期调控机制：CREPT成为癌症治疗的新兴靶点

Disrupting Cell Cycle Machinery: CREPT Is an Emerging Target in Cancer Therapy

原文发布日期：19 July 2025

DOI: 10.3390/cancers17142401

类型: Article

开放获取: 是

英文摘要：

The transcriptional co-factor cell-cycle-related and expression-elevated protein in tumors (CREPT) has emerged as a critical driver of the cell cycle and a significant contributor to tumorigenesis. The aberrant expression or upregulation of CREPT boosts multiple signaling pathways, including Wnt/β-catenin, STAT3 and NF-κB/TNFR2, which are frequently dysregulated in various cancers and are associated with poor overall survival. In preclinical studies, CREPT knockdown via shRNA has demonstrated sustained tumor growth regression. Recent researches have uncovered additional functions of CREPT, including roles in metabolic regulation, tissue repair, and microenvironmental remodeling, further establishing it as a pleiotropic transcriptional regulator. Currently, there is no therapeutic agent that directly inhibits CREPT expression in clinic. However, miRNAs and other methods have been used to target CREPT, which have yielded useful results in inhibiting tumor growth. In this review, we discuss the role of CREPT in the hallmarks of cancer and propose that targeting CREPT will reverse tumor growth and may improve the immune checkpoint inhibitors in combination in CREPT-driven cancers.

摘要翻译： 

转录共因子细胞周期相关及肿瘤表达升高蛋白（CREPT）已成为细胞周期的关键驱动因子和肿瘤发生的重要促进因素。CREPT的异常表达或上调会激活包括Wnt/β-catenin、STAT3和NF-κB/TNFR2在内的多个信号通路，这些通路在多种癌症中常发生失调，并与患者总体生存率降低相关。临床前研究表明，通过shRNA敲低CREPT表达可实现持续的肿瘤生长抑制。最新研究揭示了CREPT在代谢调控、组织修复及微环境重塑等方面的新功能，进一步确立了其作为多效性转录调节因子的地位。目前临床上尚无直接抑制CREPT表达的治疗药物，但通过miRNA及其他靶向CREPT的方法已在抑制肿瘤生长方面取得显著成效。本综述系统探讨了CREPT在癌症特征性标志中的作用，并提出靶向CREPT不仅能逆转肿瘤生长，还可能增强免疫检查点抑制剂在CREPT驱动型癌症中的联合治疗效果。

原文链接：

Disrupting Cell Cycle Machinery: CREPT Is an Emerging Target in Cancer Therapy